AIM: To analyze loss of heterozygosity (LOH) and homozygous deletion on p53 gene (exon2-3, 4 and 11), chromosome 10q22-10q23 and 22q11.2 -22q12.1 in human hepatocellular carcinoma (HCC). METHODS: PCR and PCR-based microsatellite polymorphism analysis techniques were used. RESULTS: LOH was observed at D10S579 (10q22-10q23) in 4 of 20 tumors (20%), at D22S421 (22q11.2-22q12.1) in 3 of 20(15%), at TP53.A (p53 gene exon 2-3) in 4 of 20(20%), at TP53.B (p53 gene exon 4) in 6 of 20(30%), and at TP53.G (p53 gene exon 11) in 0 of 20(0%). Homozygous deletion was detected at 10q22-10q23(8/20; 40%), 22q11.2-22q12.1(8/20; 40%), p53 gene exon 2-3(0/20;0%), p53 gene exon 4(6/20; 30%), and p53 gene exon 11(2/20; 10%). CONCLUSION: There might be unidentified tumor suppressor genes on chromosome 10q22-10q23 and 22q11.2-22q12.1 that contribute to the pathogenesis and development of HCC.
AIM: To analyze loss of heterozygosity (LOH) and homozygous deletion on p53 gene (exon2-3, 4 and 11), chromosome 10q22-10q23 and 22q11.2 -22q12.1 in humanhepatocellular carcinoma (HCC). METHODS: PCR and PCR-based microsatellite polymorphism analysis techniques were used. RESULTS: LOH was observed at D10S579 (10q22-10q23) in 4 of 20 tumors (20%), at D22S421 (22q11.2-22q12.1) in 3 of 20(15%), at TP53.A (p53 gene exon 2-3) in 4 of 20(20%), at TP53.B (p53 gene exon 4) in 6 of 20(30%), and at TP53.G (p53 gene exon 11) in 0 of 20(0%). Homozygous deletion was detected at 10q22-10q23(8/20; 40%), 22q11.2-22q12.1(8/20; 40%), p53 gene exon 2-3(0/20;0%), p53 gene exon 4(6/20; 30%), and p53 gene exon 11(2/20; 10%). CONCLUSION: There might be unidentified tumor suppressor genes on chromosome 10q22-10q23 and 22q11.2-22q12.1 that contribute to the pathogenesis and development of HCC.
Authors: P Leuraud; Y Marie; E Robin; S Huguet; J He; K Mokhtari; P Cornu; K Hoang-Xuan; M Sanson Journal: J Neurooncol Date: 2000-12 Impact factor: 4.130
Authors: M E Handel-Fernandez; M Nassiri; M Arana; M M Perez; M Fresno; M Nadji; V Vincek Journal: Anticancer Res Date: 2000 Nov-Dec Impact factor: 2.480
Authors: Nirmitha I Herath; Michael C Kew; Michael D Walsh; Joanne Young; Lawrie W Powell; Barbara A Leggett; Graeme A MacDonald Journal: J Gastroenterol Hepatol Date: 2002-03 Impact factor: 4.029
Authors: A Mohyuddin; W J Neary; A Wallace; C L Wu; S Purcell; H Reid; R T Ramsden; A Read; G Black; D G R Evans Journal: J Med Genet Date: 2002-05 Impact factor: 6.318
Authors: P Saelee; S Wongkham; V Bhudhisawasdi; B Sripa; S Chariyalertsak; S Petmitr Journal: J Cancer Res Clin Oncol Date: 2008-04-02 Impact factor: 4.553
Authors: Ana R Gomes; Ana M Abrantes; Ana F Brito; Mafalda Laranjo; João E Casalta-Lopes; Ana C Gonçalves; Ana B Sarmento-Ribeiro; Maria F Botelho; José G Tralhão Journal: Clin Mol Hepatol Date: 2015-09-30